TPTom G. Punnen

Tom G. Punnen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tom G. Punnen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Darin T. Okuda

    The University of Texas Southwestern Medical Center, Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, TX, USA; The University of Texas Southwestern Medical Center, Peter O'Donnell Jr. Brain Institute, Dallas, TX, USA

    2 shared publications
  • Mahi A. Patel

    College of Osteopathic Medicine, Kansas City University, Kansas City, MO, USA

    2 shared publications
  • Morgan McCreary

    Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    2 shared publications
  • Olaf Stüve

    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

    2 shared publications
  • Peter V. Sguigna

    Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    2 shared publications
  • Tatum M. Moog

    From the The University of Texas Southwestern Medical Center (D.T.O., T.G.P., T.M.M., M.C.M., K.W.B.), Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, Texas

    2 shared publications

Latest Publications

  • Open Access

    Selective Multi-Analyte Serum Protein Differences Between Gilenya and Generic Fingolimod in Multiple Sclerosis

    by Darin T. Okuda, Isabella J. Huddleston, Morgan C. McCreary, Katy W. Burgess, Crystal M. Wright, Darina Dinov, Tatum M. Moog, Jose Santoyo, Peter V. Sguigna, Olaf Stüve, et al.

  • Open Access

    Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod

    by Mahi A Patel, Tom G Punnen, Kevin S Shan, Morgan C McCreary, Crystal M Wright, Shanan B Munoz, Paula Hardeman, Katy W Burgess, Benjamin M Greenberg, Lindsay A Horton, et al.

    Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.


  • Open Access

    Patient Participation in AI for Health Curriculum

    by Kirsten Ostherr, Waverly Huang, Ana Park, Tom Punnen, Bhavik Tadigotla, Valencia Robinson, Andrea Downing

    The adoption of artificial intelligence (AI) in health care has outpaced education of the clinical workforce on responsible use of AI in patient care. Although many policy statements advocate safe, ethical, and trustworthy AI, guidance on the use of health AI has rarely included patient perspectives. This gap leaves out a valuable source of information and guidance about what responsible AI means to patients. In this viewpoint coauthored by patients, students, and faculty, we discuss a novel approach to integrating patient perspectives in undergraduate premedical education in the United States that aims to foster an inclusive and patient-centered future of AI in health care.


  • Open Access

    Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series

    by Darin T. Okuda, Lauren M. Tardo, Crystal M. Wright, Shanan B. Munoz, Tom G. Punnen, Mahi A. Patel, Tatum M. Moog, Katy W. Burgess

    An expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently. Generic specialty medications aim to provide greater access to molecules that alter the disease trajectory at lower costs. The US Food and Drug Administration requires generic products to contain between 90% and 110% of the stated active ingredient and an 80%–125% bioequivalence range. We present the clinical experiences and absolute lymphocyte counts (ALC) trends of six people with MS originally treated with Gilenya® (fingolimod) 0.5 mg who were required to transition to generic fingolimod 0.5 mg by third-party administrators, and the medication content from recovered products. Six individuals with acute clinical exacerbations or disease advancement on MRI were identified during routine scheduled visits from a tertiary care center and consecutively included from January 2024 to August 2024. ALC trends were constructed for each individual during Gilenya® and generic fingolimod treatment. These individuals experienced signs of disease advancement while on generic fingolimod 0.5 mg at approximately 1 year of treatment and elevations in ALC, a biological metric related to the mechanism of action of sphingsine-1-phosphate receptor modulation, were observed following the transition. High purity fingolimod for standardization tests, Gilenya® 0.5 mg, and five recovered generic fingolimod 0.5 mg products were independently tested in an accredited laboratory. Gilenya® 0.5 mg capsules had an average fingolimod content of 97.7% (standard deviation (SD) = 2.59%). Three recovered generic fingolimod 0.5 mg products used during relapses had an average content of 91.2% (3.25%), 81.6% (6.24%), and 72.5% (2.05%). Two generic fingolimod 0.5 mg products not associated with relapse activity revealed averages of 97.4% (1.82%) and 103.3% (3.77%). Subpotent generic specialty DMTs may not only result in greater risk for disease activity but may also expose individuals to the potential for disease rebound, depending on the mechanism of action.